Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)

被引：13
|
作者：
Zboralski, D. [1 ]
Osterkamp, F. [2 ]
Simmons, A. D. [3 ]
Bredenbeck, A. [4 ]
Schumann, A. [4 ]
Paschke, M. [5 ]
Beindorff, N. [6 ]
Mohan, A-M. [7 ]
Nguyen, M. [3 ]
Xiao, J. [8 ,9 ]
Harding, T. C. [3 ]
Hoehne, A. [10 ]
Reineke, U. [11 ]
Smerling, C. [12 ]
机构：
[1] 3B Pharmaceut GmbH, Assay Unit, Berlin, Germany
[2] 3B Pharmaceut GmbH, Chem & Analyt, Berlin, Germany
[3] Clovis Oncol Inc, Translat Med, Boulder, CO USA
[4] 3B Pharmaceut GmbH, Nucl Med, Berlin, Germany
[5] 3B Pharmaceut GmbH, Biol & Assay Dev, Berlin, Germany
[6] Charite Univ Med Berlin, Berlin Expt Radionuclide Imaging Ctr BERIC, Berlin, Germany
[7] Charite Univ Med Berlin, Dept Nucl Med, Berlin, Germany
[8] Clovis Oncol Inc, Clin Pharmacol, Boulder, CO USA
[9] Clovis Oncol Inc, DMPK, Boulder, CO USA
[10] 3B Pharmaceut GmbH, Radiopharmaceut Technol, Berlin, Germany
[11] 3B Pharmaceut GmbH, Berlin, Germany
[12] 3B Pharmaceut GmbH, Nucl Med & Imaging, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.685
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
571P
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [1] Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
    Dirk Zboralski
    Aileen Hoehne
    Anne Bredenbeck
    Anne Schumann
    Minh Nguyen
    Eberhard Schneider
    Jan Ungewiss
    Matthias Paschke
    Christian Haase
    Jan L. von Hacht
    Tanya Kwan
    Kevin K. Lin
    Jan Lenore
    Thomas C. Harding
    Jim Xiao
    Andrew D. Simmons
    Ajay-Mohan Mohan
    Nicola Beindorff
    Ulrich Reineke
    Christiane Smerling
    Frank Osterkamp
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3651 - 3667
  • [2] Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
    Zboralski, Dirk
    Hoehne, Aileen
    Bredenbeck, Anne
    Schumann, Anne
    Nguyen, Minh
    Schneider, Eberhard
    Ungewiss, Jan
    Paschke, Matthias
    Haase, Christian
    von Hacht, Jan L.
    Kwan, Tanya
    Lin, Kevin K.
    Lenore, Jan
    Harding, Thomas C.
    Xiao, Jim
    Simmons, Andrew D.
    Mohan, Ajay-Mohan
    Beindorff, Nicola
    Reineke, Ulrich
    Smerling, Christiane
    Osterkamp, Frank
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (11) : 3651 - 3667
  • [3] Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286
    Kwan, Tanya T.
    Nguyen, Minh
    Zboralski, Dirk
    Schumann, Anne
    Bredenbeck, Anne
    Paschke, Matthias
    Haase, Christian
    Hoehne, Aileen
    Reineke, Ulrich
    Smerling, Christiane
    Osterkamp, Frank
    Xiao, Jim
    Simmons, Andrew D.
    Harding, Thomas C.
    Lin, Kevin L.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [4] Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: Feasibility, Biodistribution and Preliminary Dosimetry in a First-in-human study
    Baum, Richard
    Chantadisai, Maythinee
    Smerling, Christiane
    Schuchardt, Christiane
    Singh, Aviral
    Eismant, Alexander
    Almaguel, Frankis
    Mueller, Dirk
    Zboralski, Dirk
    Osterkamp, Frank
    Hoehne, Aileen
    Reineke, Ulrich
    Kulkarni, Harshad
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [5] Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46
    Zboralski, Dirk
    Hoehne, Aileen
    Bredenbeck, Anne
    Paschke, Matthias
    von Hacht, Jan Lennart
    Xiao, Jim
    Simmons, Andrew D.
    Osterkamp, Frank
    Harding, Thomas
    Minh Nguyen
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results
    Kulkarni, H.
    Smerling, C.
    Schuchardt, C.
    Singh, A.
    Robiller, F.
    Chantadisai, M.
    Eismant, A.
    Mueller, D.
    Zboralski, D.
    Osterkamp, F.
    Hoehne, A.
    Reineke, U.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S280 - S280
  • [7] Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Rubel Chakravarty
    Wenyu Song
    Sudipta Chakraborty
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2935 - 2939
  • [8] Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Chakravarty, Rubel
    Song, Wenyu
    Chakraborty, Sudipta
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (10) : 2935 - 2939
  • [9] Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
    Muhsin H. Younis
    Sara Malih
    Xiaoli Lan
    Mohammad Javad Rasaee
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 1773 - 1777
  • [10] Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond
    Younis, Muhsin H.
    Malih, Sara
    Lan, Xiaoli
    Rasaee, Mohammad Javad
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (06) : 1773 - 1777
12345